Literature DB >> 9040634

Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model.

C W Daggett1, M Yeatman, A J Lodge, E P Chen, P Van Trigt, G W Byrne, J S Logan, J H Lawson, J L Platt, R D Davis.   

Abstract

UNLABELLED: Pulmonary transplantation is currently limited by the number of suitable cadaver donor lungs. For this reason, pulmonary xenotransplantation is currently being investigated.
OBJECTIVE: Our goal was to assess the role of complement in pulmonary xenograft dysfunction.
METHODS: The pulmonary function of swine expressing human decay accelerating factor and human CD59 (n = 6) was compared with that of the lungs from nontransgenic (control) swine (n = 6) during perfusion with human plasma.
RESULTS: After 2 hours of perfusion, the pulmonary vascular resistance was 1624 +/- 408 dynes.sec.cm-5 in control lungs and 908 +/- 68 dynes.sec.cm-5 in transgenic lungs (p < 0.05). Control lungs had a venous oxygen tension of 271 +/- 23 mm Hg with a ratio of venous oxygen tension to inspired oxygen fraction of 452 +/- 38 at 2 hours of perfusion; transgenic lungs had a venous oxygen tension of 398 +/- 11 mm Hg and a ratio of venous oxygen tension to inspired oxygen fraction of 663 +/- 18 (p < 0.05). Control lungs showed a decrease of 79.8% +/- 3.7% in static pulmonary compliance by 2 hours, versus a 12.0% +/- 8.1% decrease by the transgenic lungs (p < 0.05). The control lungs also developed 561.7 +/- 196.2 ml of airway edema over 2 hours, in contrast to 6.5 +/- 1.7 ml in transgenic lungs (p < 0.05).
CONCLUSION: Lungs from swine expressing human decay accelerating factor and human CD59 functioned better than nontransgenic swine lungs when perfused with human plasma. These results suggest that complement activation is involved in producing acute pulmonary xenograft dysfunction and demonstrate that lungs from swine expressing human decay accelerating factor and human CD59 are protected against pulmonary injury when perfused with human plasma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040634     DOI: 10.1016/S0022-5223(97)70337-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

Review 1.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 2.  Lung xenotransplantation: recent progress and current status.

Authors:  Donald G Harris; Kevin J Quinn; Siamak Dahi; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-07-05       Impact factor: 3.907

Review 3.  Overcoming Coagulation Dysregulation in Pig Solid Organ Transplantation in Nonhuman Primates: Recent Progress.

Authors:  Liaoran Wang; David K C Cooper; Lars Burdorf; Yi Wang; Hayato Iwase
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 4.  Lung xenotransplantation: a review.

Authors:  Chris Laird; Lars Burdorf; Richard N Pierson
Journal:  Curr Opin Organ Transplant       Date:  2016-06       Impact factor: 2.640

5.  Generation of GTKO Diannan Miniature Pig Expressing Human Complementary Regulator Proteins hCD55 and hCD59 via T2A Peptide-Based Bicistronic Vectors and SCNT.

Authors:  Fengjuan Liu; Jinji Liu; Zaimei Yuan; Yubo Qing; Honghui Li; Kaixiang Xu; Wanyun Zhu; Heng Zhao; Baoyu Jia; Weirong Pan; Jianxiong Guo; Xuezeng Zhang; Wenmin Cheng; Wei Wang; Hong-Ye Zhao; Hong-Jiang Wei
Journal:  Mol Biotechnol       Date:  2018-08       Impact factor: 2.695

6.  Meta-analysis of the independent and cumulative effects of multiple genetic modifications on pig lung xenograft performance during ex vivo perfusion with human blood.

Authors:  Donald G Harris; Kevin J Quinn; Beth M French; Evan Schwartz; Elizabeth Kang; Siamak Dahi; Carol J Phelps; David L Ayares; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-12-02       Impact factor: 3.907

Review 7.  Complement-mediated microvascular injury leads to chronic rejection.

Authors:  Mohammad A Khan; Mark R Nicolls
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

8.  Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen.

Authors:  Amanda Mener; Connie M Arthur; Seema R Patel; Jingchun Liu; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-06-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.